Quanta Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Tower Pl Fl 14, South San Francisco, C...Phone Number
(661) 992-6907Website
www.quantatx.comRevenue
$8.4 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Quanta Therapeutics
Based in San Francisco since 2018, Quanta Therapeutics is a biopharmaceutical company. Quanta's team has engineered a platform that uses detection technology and sophisticated medicinal chemistry to develop molecules as medicines.Explore more
Quanta Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Quanta Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Quanta Therapeutics is spiking on competitors!
Quanta Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Quanta Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Quanta Therapeutics launches new products
Funding: Get notified immidiatlly once Quanta Therapeutics has new funding data
Check if Quanta Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Quanta Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Quanta Therapeutics
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Quanta Therapeutics
Compare insights from companies similar to Quanta Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Quanta Therapeutics
$8.4M
11-50
Private
$110M
2018
Vanessa JacobyChief Business Officer & Chief Financial Officer
Company Profile Activity
Activity Insights
Quanta Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Quanta Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Quanta Therapeutics.
Quanta Therapeutics financials insights
Gather financial insights about Quanta Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series C
$60M
2023
Series D
$50M
Quanta Therapeutics Tech Stack
A closer look at the technologies used by Quanta Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Project
Research & Development, Compliance, Medical Research, Regulations
Quanta Therapeutics News & Media
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors
Quanta presented positive Phase 1 data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with advanced cancer, including CRC, PDACQuanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral therapeutics for RAS-driven cancers, today announced it will present Phase 1 clinical data on QTX3034 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 2025 in Boston, Mass. QTX3034 is an oral, G12D-preferring, multi-KRAS inhQuanta Announces Leadership Team Appointment and Highlights Clinical Program Progress
– 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership –Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
- Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity -
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Quanta Therapeutics
Sign Up For FreeTo access detailed company insights
Based in San Francisco since 2018, Quanta Therapeutics is a biopharmaceutical company. Quanta's team has engineered a platform that uses detection technology and sophisticated medicinal chemistry to develop molecules as medicines.... Read More
